# TransMedics Group Inc. (TMDX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Health Care Technology. Price $89.98, market value $3.1 billion.

## Valuation
- **P/E (trailing): 23.3×** (5-yr avg 43.4×, 3-yr avg 43.4×). TransMedics Group Inc. trades at 23.3× trailing earnings, well below its own five-year average of 43.4×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 39.0×, higher than trailing, so analysts expect earnings to fall.
- **PEG: 0.10**. A PEG of 0.10 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 4.7×**. Each dollar of revenue is priced at 4.7×.
- **Price / book: 6.0×**. The shares trade at 6.0× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 26.5×**. Enterprise value is 26.5× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 2.5%** (5-yr avg -3.3%). Free cash flow equals 2.5% of the market value, above its five-year average of -3.3%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 4.3%**. The inverse of the P/E: 4.3% of the price is earned each year.

## Profitability
- **Gross margin: 58.7%**. TransMedics Group Inc. keeps 58.7% of revenue after the direct cost of what it sells.
- **Operating margin: 12.2%**. 12.2% of revenue is left after running the business.
- **Net margin: 31.4%**. 31.4% of each dollar of sales reaches the bottom line.
- **Return on equity: 40.2%**. 40.2% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 13.3%**. Return on all capital, debt included, is 13.3%.
- **Return on assets: 14.2%**. Each dollar of assets produces 14.2% of profit.

## Growth
- **Revenue growth (1 yr): 37.1%** (3-yr 86.4%/yr, 5-yr 84.5%/yr). Revenue grew 37.1% over the last year, against 84.5% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 382.2%**. Earnings per share rose 382.2%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.02**. Debt is 0.02 times equity: a conservative balance sheet.
- **Current ratio: 7.14** (quick 7.14). Current assets cover the next year's liabilities 7.14 times.
- **Altman Z-score: 5.28**. A Z-score of 5.28 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 7/9**. 7 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend: none**. TransMedics Group Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (10 analysts). 10 analysts cover TransMedics Group Inc.; the consensus is buy, with an average price target of $97.30 (+8% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -13.5%** (YTD -26.0%, 3-mo 29.6%). The shares are down 13.5% over twelve months including dividends.
- **From 52-week high: -42.3%** (49.7% above the low). Trading 42% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 57**. An RSI of 57 is neutral.
- **Beta (1 yr): 1.16** (volatility 57%). Beta of 1.16 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=TMDX · Page: https://foliofundamentals.com/stocks/tmdx

Not investment advice.